Table 3.
Long-term follow-up.
| Total Population, n = 699 | Large Vessels, n = 362 | Small Vessels, n = 337 | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Small Vessels n = 337 |
Large Vessels n = 362 |
p Value | DES 1 n = 144 |
DES 2 n = 218 |
p Value | DES 1 n = 104 |
DES 2 n = 233 |
p Value | |
| Efficacy | |||||||||
| MACCE | 68 (20%) | 50 (14%) | 0.025 | 30 (21%) | 20 (9.2%) | 0.002 | 27 (26%) | 41 (18%) | 0.08 |
| Death | 13 (3.9%) | 6 (1.7%) | 0.074 | 3 (2.1%) | 3 (1.4%) | 0.67 | 7 (6.7%) | 6 (2.6%) | 0.07 |
| Non-fatal AMI | 31 (9.2%) | 29 (8.0%) | 0.58 | 16 (11%) | 13 (6.0%) | 0.08 | 12 (12%) | 19 (8.2%) | 0.32 |
| Re-PCI (TVR) | 34 (10%) | 34 (9.4%) | 0.76 | 21 (15%) | 13 (6.0%) | 0.006 | 13 (13%) | 21 (9.0%) | 0.33 |
| Stroke | 12 (3.6%) | 5 (1.4%) | 0.062 | 4 (2.8%) | 1 (0.5%) | 0.08 | 4 (3.8%) | 8 (3.4%) | 1.00 |
| Safety | |||||||||
| Stent thrombosis 1 | 3 (0.9%) | 6 (1.7%) | 0.51 | 5 (3.5%) | 1 (0.5%) | 0.04 | 2 (1.9%) | 1 (0.4%) | 0.23 |
| acute | 1 (0.3%) | 3 (0.8%) | 0.63 | 3 (2.1%) | 0 (0%) | 0.06 | 1 (1%) | 0 (0%) | 0.31 |
| subacute | 1 (0.3%) | 2 (0.6%) | 1.0 | 1 (0.7%) | 1 (0.5%) | 1.00 | 0 (0%) | 1 (0.4%) | 1.00 |
| late | 1 (0.3%) | 1 (0.3%) | 1.0 | 1 (0.7%) | 0 (0%) | 0.39 | 1 (0.96%) | 0 (0%) | 0.31 |
| Very late | 0 (0%) | 0 (0%) | - | 0 (0%) | 0 (0%) | - | 0 (0%) | 0 (0%) | - |
Data are presented as n (%). DES—drug-eluting stent, MACCE—major adverse cardiac and cerebrovascular event, AMI—acute myocardial infarction, PCI—percutaneous coronary intervention, TVR—target vessel revascularization. 1 Definite stent thrombosis according to ARC (Academic Research Consortium).